<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-INR-16007756</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-01-15</date_registration>
      <primary_sponsor>the First Affiliated Hospital of Soochow University</primary_sponsor>
      <public_title> Pre-emptive therapy of interferon alpha-2b and decitibine in leukemia patients with relapsing tendencies after allogeneic hematopoietic stem cell transplantation: a prospective randomized controlled clinical study</public_title>
      <acronym />
      <scientific_title> pre-emptive therapy of interferon alpha-2b and decitibine in leukemia patients with relapsing tendencies after allogeneic hematopoietic stem cell transplantation: a prospective randomized controlled clinical study</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-01-15</date_enrolment>
      <type_enrolment />
      <target_size> interferon α-2b and decitibine group:60;donor lymphocyte transfusions group:30;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=12951</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Acute leukemia</hc_freetext>
      <i_freetext> interferon α-2b and decitibine group:pre-emptive therapy of interferon α-2b and decitibine;donor lymphocyte transfusions group:pre-emptive therapy of donor lymphocyte transfusions;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Tang XiaoWen</firstname>
        <middlename />
        <lastname />
        <address>188 Shizi Road, Suzhou, Jiangsu, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13913538266</telephone>
        <email>xwtang1020@163.com</email>
        <affiliation>the First Affiliated Hospital of Soochow University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Wu Depei、Tang XiaoWen</firstname>
        <middlename />
        <lastname />
        <address>188 Shizi Road, Suzhou, Jiangsu, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13913538266</telephone>
        <email>xwtang1020@163.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. with inform consent;
2. Aged 12-60 years;
3. At least one of the following conditions with relapse tendency were met:
(1) 3–5% bone marrow blasts;
(2) MRD &gt;=1*10^3;
(3) Positive specific fusion gene detection or WT-1 gene copy number &gt; 200 copies/10,000 abl copies;
(4) DC &lt;=90% detected by short tandem repeat (STR) technology; 
4.No contraindication for pre-emptive therapy: active infection, liver and renal function damage.</inclusion_criteria>
      <agemin>12</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. uncontrolled infection or significant bleeding;
2. Organ failure;
3. over grade III graft-versus-host disease (GVHD) of patients with relapse tendency;
4. hematologic relapse.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Disease-free survival;Overall Survival;Disease Response;accumulated disease progressed or inefficiency rate;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Non-hematologic toxicity;hematologic toxicity;graft-versus-host disease;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-12-01</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>